Skeletal and soft tissue sarcomas. Treatment with adjuvant immunotherapy.
Because there is evidence for an active immunologic response against sarcoma, a clinical trial of adjuvant immunotherapy using bacillus Calmette-Guérin (BCG) and tumor cell vaccine was begun. Eleven of 18 patients with localized soft tissue sarcoma who received immunotherapy are free of disease, compared to only 5 of 15 treated by operation alone who are free of disease. Furthermore, immunotherapy also prolonged the median disease-free interval from 7.3 months to 15 months in the patients who experienced recurrence of their disease.
D001500:BCG Vaccine / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D011182:Postoperative Care; D012008:Recurrence; D012075:Remission, Spontaneous; D012509:Sarcoma / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*
D001500:BCG Vaccine